98 related articles for article (PubMed ID: 8273564)
1. Characterization of a tight-binding MMP-3 inhibitor using improved fluorescence spectroscopy techniques.
Finch-Arietta M; Johnson W; Lusch L; Fotouhi N; Walsky R; Hanglow AC
Agents Actions; 1993; 39 Spec No():C189-91. PubMed ID: 8273564
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
[TBL] [Abstract][Full Text] [Related]
3. A high throughput fluorogenic substrate for stromelysin (MMP-3).
Bickett DM; Green MD; Wagner C; Roth JT; Berman J; McGeehan GM
Ann N Y Acad Sci; 1994 Sep; 732():351-5. PubMed ID: 7978805
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor.
Nar H; Werle K; Bauer MM; Dollinger H; Jung B
J Mol Biol; 2001 Sep; 312(4):743-51. PubMed ID: 11575929
[TBL] [Abstract][Full Text] [Related]
5. Solution structure of the catalytic domain of human stromelysin complexed with a hydrophobic inhibitor.
Van Doren SR; Kurochkin AV; Hu W; Ye QZ; Johnson LL; Hupe DJ; Zuiderweg ER
Protein Sci; 1995 Dec; 4(12):2487-98. PubMed ID: 8580839
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2, a fluorogenic substrate with increased specificity constants for collagenases and tumor necrosis factor converting enzyme.
Neumann U; Kubota H; Frei K; Ganu V; Leppert D
Anal Biochem; 2004 May; 328(2):166-73. PubMed ID: 15113693
[TBL] [Abstract][Full Text] [Related]
7. Application of N-carboxyalkyl peptides to the inhibition and affinity purification of the porcine matrix metalloproteinases collagenase, gelatinase, and stromelysin.
Stack MS; Emberts CG; Gray RD
Arch Biochem Biophys; 1991 Jun; 287(2):240-9. PubMed ID: 1654808
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.
Esser CK; Bugianesi RL; Caldwell CG; Chapman KT; Durette PL; Girotra NN; Kopka IE; Lanza TJ; Levorse DA; MacCoss M; Owens KA; Ponpipom MM; Simeone JP; Harrison RK; Niedzwiecki L; Becker JW; Marcy AI; Axel MG; Christen AJ; McDonnell J; Moore VL; Olszewski JM; Saphos C; Visco DM; Hagmann WK
J Med Chem; 1997 Mar; 40(6):1026-40. PubMed ID: 9083493
[TBL] [Abstract][Full Text] [Related]
9. Bioactive conformation of stromelysin inhibitors determined by transferred nuclear Overhauser effects.
Gonnella NC; Bohacek R; Zhang X; Kolossváry I; Paris CG; Melton R; Winter C; Hu SI; Ganu V
Proc Natl Acad Sci U S A; 1995 Jan; 92(2):462-6. PubMed ID: 7831311
[TBL] [Abstract][Full Text] [Related]
10. Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.
Campbell DA; Xiao XY; Harris D; Ida S; Mortezaei R; Ngu K; Shi L; Tien D; Wang Y; Navre M; Patel DV; Sharr MA; DiJoseph JF; Killar LM; Leone CL; Levin JI; Skotnicki JS
Bioorg Med Chem Lett; 1998 May; 8(10):1157-62. PubMed ID: 9871727
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
Yamamoto M; Tsujishita H; Hori N; Ohishi Y; Inoue S; Ikeda S; Okada Y
J Med Chem; 1998 Apr; 41(8):1209-17. PubMed ID: 9548812
[TBL] [Abstract][Full Text] [Related]
12. Comparison of native matrix metalloproteinases and their recombinant catalytic domains using a novel radiometric assay.
Brownell J; Earley W; Kunec E; Morgan BA; Olyslager B; Wahl RC; Houck DR
Arch Biochem Biophys; 1994 Oct; 314(1):120-5. PubMed ID: 7944383
[TBL] [Abstract][Full Text] [Related]
13. Stereoselective binding of an enantiomeric pair of stromelysin-1 inhibitors caused by conformational entropy factors.
Parker MH; Ortwine DF; O'Brien PM; Lunney EA; Banotai CA; Mueller WT; McConnell P; Brouillette CG
Bioorg Med Chem Lett; 2000 Nov; 10(21):2427-30. PubMed ID: 11078193
[TBL] [Abstract][Full Text] [Related]
14. A recombinant human stromelysin catalytic domain identifying tryptophan derivatives as human stromelysin inhibitors.
Ye QZ; Johnson LL; Nordan I; Hupe D; Hupe L
J Med Chem; 1994 Jan; 37(1):206-9. PubMed ID: 8289198
[TBL] [Abstract][Full Text] [Related]
15. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2.
Jani M; Tordai H; Trexler M; Bányai L; Patthy L
Biochimie; 2005; 87(3-4):385-92. PubMed ID: 15781326
[TBL] [Abstract][Full Text] [Related]
16. A fluorescent peptide substrate for the surface metalloprotease of Leishmania.
Bouvier J; Schneider P; Malcolm B
Exp Parasitol; 1993 Mar; 76(2):146-55. PubMed ID: 8454023
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the binding of hydroxamic acid and carboxylic acid inhibitors to the stromelysin-1 (matrix metalloproteinase-3) catalytic domain by isothermal titration calorimetry.
Parker MH; Lunney EA; Ortwine DF; Pavlovsky AG; Humblet C; Brouillette CG
Biochemistry; 1999 Oct; 38(41):13592-601. PubMed ID: 10521266
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandins E2 and E1 inhibit cytokine-induced metalloprotease expression in human synovial fibroblasts. Mediation by cyclic-AMP signalling pathway.
DiBattista JA; Martel-Pelletier J; Fujimoto N; Obata K; Zafarullah M; Pelletier JP
Lab Invest; 1994 Aug; 71(2):270-8. PubMed ID: 8078306
[TBL] [Abstract][Full Text] [Related]
19. Hydroxamate derivatives of substrate-analogous peptides containing aminomalonic acid are potent inhibitors of matrix metalloproteinases.
Krumme D; Wenzel H; Tschesche H
FEBS Lett; 1998 Oct; 436(2):209-12. PubMed ID: 9781680
[TBL] [Abstract][Full Text] [Related]
20. Rational design of tropoelastin peptide-based inhibitors of metalloproteinases.
Jensen SA; Andersen P; Vrhovski B; Weiss AS
Arch Biochem Biophys; 2003 Jan; 409(2):335-40. PubMed ID: 12504900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
